These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 39384195)
1. HDAC inhibitor SAHA enhances antitumor immunity via the HDAC1/JAK1/FGL1 axis in lung adenocarcinoma. Xu T; Fang Y; Gu Y; Xu D; Hu T; Yu T; Xu YY; Shen HY; Ma P; Shu Y J Immunother Cancer; 2024 Oct; 12(10):. PubMed ID: 39384195 [TBL] [Abstract][Full Text] [Related]
2. HDAC is indispensable for IFN-γ-induced B7-H1 expression in gastric cancer. Deng R; Zhang P; Liu W; Zeng X; Ma X; Shi L; Wang T; Yin Y; Chang W; Zhang P; Wang G; Tao K Clin Epigenetics; 2018 Dec; 10(1):153. PubMed ID: 30537988 [TBL] [Abstract][Full Text] [Related]
3. Suberanilohydroxamic acid (SAHA), a HDAC inhibitor, suppresses the effect of Treg cells by targeting the c-Myc/CCL1 pathway in glioma stem cells and improves PD-L1 blockade therapy. Sun T; Liu B; Cai L; Zhou Y; Yang W; Li Y J Neurooncol; 2024 Jul; 168(3):457-471. PubMed ID: 38652401 [TBL] [Abstract][Full Text] [Related]
4. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma. Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373 [TBL] [Abstract][Full Text] [Related]
5. FOXA1/UBE2T Inhibits CD8 Pu J; Zhang D; Wang B; Zhu P; Yang W; Wang K; Yang Z; Song Q Front Biosci (Landmark Ed); 2024 Apr; 29(4):134. PubMed ID: 38682180 [TBL] [Abstract][Full Text] [Related]
6. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA. Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915 [TBL] [Abstract][Full Text] [Related]
7. Effects of novel HDAC inhibitors on urothelial carcinoma cells. Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501 [TBL] [Abstract][Full Text] [Related]
8. Enhancement of Histone Deacetylase Inhibitor Sensitivity in Combination with Cyclin-Dependent Kinase Inhibition for the Treatment of Oral Squamous Cell Carcinoma. Zhao B; Huang Z; Qin Z; Li Y; Wang T; Wang L; Zhou W; Yu C; Wang X; Yang S; Fan Y; Xiang R Cell Physiol Biochem; 2019; 53(1):141-156. PubMed ID: 31237760 [TBL] [Abstract][Full Text] [Related]
9. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790 [TBL] [Abstract][Full Text] [Related]
10. Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer. Shin HS; Choi J; Lee J; Lee SY Cancer Res Treat; 2022 Apr; 54(2):458-468. PubMed ID: 34517693 [TBL] [Abstract][Full Text] [Related]
11. Discovery of a novel hybrid coumarin-hydroxamate conjugate targeting the HDAC1-Sp1-FOSL2 signaling axis for breast cancer therapy. Zhu S; Zhu W; Zhao K; Yu J; Lu W; Zhou R; Fan S; Kong W; Yang F; Shan P Cell Commun Signal; 2024 Jul; 22(1):361. PubMed ID: 39010083 [TBL] [Abstract][Full Text] [Related]
12. SAHA inhibits the growth of colon tumors by decreasing histone deacetylase and the expression of cyclin D1 and survivin. Jin JS; Tsao TY; Sun PC; Yu CP; Tzao C Pathol Oncol Res; 2012 Jul; 18(3):713-20. PubMed ID: 22270866 [TBL] [Abstract][Full Text] [Related]
13. Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling. Huang Z; Zhou W; Li Y; Cao M; Wang T; Ma Y; Guo Q; Wang X; Zhang C; Zhang C; Shen W; Liu Y; Chen Y; Zheng J; Yang S; Fan Y; Xiang R Theranostics; 2018; 8(18):4995-5011. PubMed ID: 30429882 [TBL] [Abstract][Full Text] [Related]
14. HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma. Zheng H; Zhao W; Yan C; Watson CC; Massengill M; Xie M; Massengill C; Noyes DR; Martinez GV; Afzal R; Chen Z; Ren X; Antonia SJ; Haura EB; Ruffell B; Beg AA Clin Cancer Res; 2016 Aug; 22(16):4119-32. PubMed ID: 26964571 [TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitor attenuates experimental fungal keratitis in mice. Li X; Yuan M; Yin R; Liu X; Zhang Y; Sun S; Han L; He S Sci Rep; 2019 Jul; 9(1):9859. PubMed ID: 31285488 [TBL] [Abstract][Full Text] [Related]
16. Combination of rapamycin and SAHA enhanced radiosensitization by inducing autophagy and acetylation in NSCLC. Wang Y; Liu F; Fang C; Xu L; Chen L; Xu Z; Chen J; Peng W; Fu B; Li Y Aging (Albany NY); 2021 Jul; 13(14):18223-18237. PubMed ID: 34321364 [TBL] [Abstract][Full Text] [Related]
17. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855 [TBL] [Abstract][Full Text] [Related]
18. Controlled release of an HDAC inhibitor for reduction of inflammation in dry eye disease. Ratay ML; Balmert SC; Bassin EJ; Little SR Acta Biomater; 2018 Apr; 71():261-270. PubMed ID: 29526828 [TBL] [Abstract][Full Text] [Related]
19. HES6 Mediates Oxidative Phosphorylation Pathway to Promote Immune Infiltration of CD8 + T Cells in Lung Adenocarcinoma. Chen Z; Wang Y; Tang W; Xu S; Yu H; Chen Z J Immunother; 2024 Oct; 47(8):313-322. PubMed ID: 39005046 [TBL] [Abstract][Full Text] [Related]
20. The deubiquitinase USP2a promotes tumor immunosuppression by stabilizing immune checkpoint B7-H4 in lung adenocarcinoma harboring EGFR-activating mutants. Lu Y; Sun Y; Zhang J; Kong M; Zhao Z; Sun B; Wang Y; Jiang Y; Chen S; Wang C; Tong Y; Wen L; Huang M; Wu F; Zhang L Cancer Lett; 2024 Aug; 596():217020. PubMed ID: 38849009 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]